365 related articles for article (PubMed ID: 19298583)
21. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Hobday T; Castellano D; Reidy-Lagunes D; García-Carbonero R; Carrato A
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():19-26. PubMed ID: 21308478
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
23. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Johnson PR
Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
[TBL] [Abstract][Full Text] [Related]
24. State of the art and future prospects in the management of neuroendocrine tumors.
Oberg K
Q J Nucl Med; 2000 Mar; 44(1):3-12. PubMed ID: 10932597
[TBL] [Abstract][Full Text] [Related]
25. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors.
Turaga KK; Kvols LK
CA Cancer J Clin; 2011; 61(2):113-32. PubMed ID: 21388967
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine tumors. Peptide receptor radionuclide therapy.
Forrer F; Valkema R; Kwekkeboom DJ; de Jong M; Krenning EP
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):111-29. PubMed ID: 17382268
[TBL] [Abstract][Full Text] [Related]
27. An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach.
Kuiper P; Verspaget HW; Overbeek LI; Biemond I; Lamers CB
Neth J Med; 2011 Jan; 69(1):14-20. PubMed ID: 21325696
[TBL] [Abstract][Full Text] [Related]
28. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.
Strosberg JR; Cheema A; Kvols LK
Cancer Control; 2011 Apr; 18(2):127-37. PubMed ID: 21451455
[TBL] [Abstract][Full Text] [Related]
29. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review.
Srirajaskanthan R; McStay M; Toumpanakis C; Meyer T; Caplin ME
Neuroendocrinology; 2009; 89(1):48-55. PubMed ID: 18679021
[TBL] [Abstract][Full Text] [Related]
30. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Faivre S; Sablin MP; Dreyer C; Raymond E
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
[TBL] [Abstract][Full Text] [Related]
31. Medical management of pancreatic neuroendocrine tumors.
Delaunoit T; Neczyporenko F; Rubin J; Erlichman C; Hobday TJ
Am J Gastroenterol; 2008 Feb; 103(2):475-83; quiz 484. PubMed ID: 18028508
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.
Appetecchia M; Baldelli R
J Exp Clin Cancer Res; 2010 Mar; 29(1):19. PubMed ID: 20196864
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic and diagnostic implications of the somatostatin system in gastroenteropancreatic neuroendocrine tumour disease.
Höcker M; Wiedenmann B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S139-42. PubMed ID: 10604118
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
Oberg K
Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
[TBL] [Abstract][Full Text] [Related]
35. [Pharmacologic therapy for neuroendocrine tumours].
Petrányi A; Bodoky G
Orv Hetil; 2011 Mar; 152(10):379-91. PubMed ID: 21354954
[TBL] [Abstract][Full Text] [Related]
36. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
Cloyd JM; Konda B; Shah MH; Pawlik TM
Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
[TBL] [Abstract][Full Text] [Related]
37. [Neuroendocrine tumors: the age of targeted therapies].
Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
Grozinsky-Glasberg S; Shimon I; Korbonits M; Grossman AB
Endocr Relat Cancer; 2008 Sep; 15(3):701-20. PubMed ID: 18524947
[TBL] [Abstract][Full Text] [Related]
39. [Neuroendocrine tumors of the digestive system].
Prónai L; Rácz K; Tulassay Z
Orv Hetil; 2002 May; 143(19 Suppl):1081-6. PubMed ID: 12063866
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic therapy of gastroenteropancreatic (GEP) tumors.
Syrigos KN; Sitara D; Georgiou E; Harrington KJ
Anticancer Res; 2002; 22(2B):1311-4. PubMed ID: 12168943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
